Premium
Impact of whole‐body MRI and FDG‐PET on staging and assessment of therapy response in a patient with Ewing sarcoma
Author(s) -
Furth C.,
Amthauer H.,
Denecke T.,
Ruf J.,
Henze G.,
Gutberlet M.
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20662
Subject(s) - medicine , sarcoma , radiology , blood cancer , radiation therapy , ewing's sarcoma , regimen , nuclear medicine , cancer , surgery , pathology
Abstract In patients with Ewing sarcoma, precise staging is not only crucial for the therapeutic regimen but also for a reliable evaluation of response to therapy. We report on a 15‐year‐old girl with metastatic spread of a Ewing sarcoma who, apart from conventional staging by bone scan, chest X‐ray and CT, was subsidiary examined by FDG‐PET and whole‐body MRI before and after chemotherapy. Both modalities detected more bone lesions than the bone scan, which led to an altered strategy for radiotherapy. Both examinations might be a great asset to stage‐adjusted therapy regimens, ultimately influencing patient outcome. Pediatr Blood Cancer 2006; 47:607–611. © 2005 Wiley‐Liss, Inc.